α-突触核蛋白种子扩增检测用于诊断突触核蛋白病:前进之路
本文综述α-突触核蛋白种子扩增检测(SAAs)在帕金森病及其他突触核蛋白病诊断中的应用。SAAs可在脑脊液、嗅黏膜、下颌下腺活检、皮肤和唾液中检测错误折叠的α-突触核蛋白,区分帕金森病、路易体痴呆与对照者,甚至在前驱期即可鉴别,并能区分帕金森病、路易体痴呆与多系统萎缩。但检测标准化等分析前和分析问题仍需解决。
要点
- SAAs可在多种基质中检测错误折叠的α-突触核蛋白,支持帕金森病等突触核蛋白病的分子诊断。
- SAAs能区分帕金森病和路易体痴呆与对照者,甚至在前驱期,并能区分突触核蛋白病与非突触核蛋白病性帕金森综合征。
- 荧光谱动力学分析可识别突触核蛋白病依赖的α-突触核蛋白纤维构象(毒株),有助鉴别路易体病与多系统萎缩。
核心结论
- α-突触核蛋白SAAs检测的播种活性是突触核蛋白病最有前景的诊断生物标志物,但检测标准化等问题仍需解决。
研究设计与样本
- 本文为综述,讨论支持α-突触核蛋白SAAs临床应用于识别帕金森病和其他突触核蛋白病的关键发现、未满足需求和未来展望。
主要发现
- SAAs已成功用于检测帕金森病和其他突触核蛋白病患者脑脊液、嗅黏膜、下颌下腺活检、皮肤和唾液中的错误折叠α-突触核蛋白。
- SAAs可将帕金森病和路易体痴呆与对照者区分,甚至在前驱期。
- 在鉴别诊断中,SAAs满意地将帕金森病、路易体痴呆和多系统萎缩与非突触核蛋白病性帕金森综合征区分。
- SAAs荧光谱动力学分析可识别突触核蛋白病依赖的α-突触核蛋白纤维构象(毒株),在区分突触核蛋白病尤其是路易体病(帕金森病和路易体痴呆)与多系统萎缩方面有诊断潜力。
局限性
- 原文指出仍存在分析前和分析问题,主要与检测标准化相关,需要解决。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Parkinson disease (PD) is the second most common neurodegenerative disease, and the most common synucleinopathy, as alpha-synuclein (α-syn), a prion-like protein, plays an important pathophysiologic role in its onset and progression. Although neuropathologic changes begin many years before the onset of motor manifestations, diagnosis still relies on the identification of the motor symptoms, which hinders to formulate an early diagnosis. Because α-syn misfolding and aggregation precede clinical manifestations, the possibility to identify these phenomena in patients with PD would allow us to recognize the disease at the earliest, premotor phases, as a consequence of the transition from a clinical to a molecular diagnosis. Seed amplification assays (SAAs) are a group of techniques that currently support the diagnosis of prion subacute encephalopathies, namely Creutzfeldt-Jakob disease. These techniques enable the detection of minimal amounts of prions in CSF and other matrices of affected patients. Recently, SAAs have been successfully applied to detect misfolded alpha-synuclein (α-syn) in CSF, olfactory mucosa, submandibular gland biopsies, skin, and saliva of patients with Parkinson disease (PD) and other synucleinopathies. In these categories, they can differentiate PD and dementia with Lewy bodies (DLBs) from control subjects, even in the prodromal stages of the disease. In differential diagnosis, SAAs satisfactorily differentiated PD, DLB, and multiple system atrophy (MSA) from nonsynucleinopathy parkinsonisms. The kinetic analysis of the SAA fluorescence profiles allowed the identification of synucleinopathy-dependent α-syn fibrils conformations, commonly referred to as strains, which have demonstrated diagnostic potential in differentiating among synucleinopathies, especially between Lewy body diseases (LBDs) (PD and DLB) and MSA. In front of these highly promising data, which make the α-syn seeding activity detected by SAAs as the most promising diagnostic biomarker for synucleinopathies, there are still preanalytical and analytical issues, mostly related to the assay standardization, which need to be solved. In this review, we discuss the key findings supporting the clinical application of α-syn SAAs to identify PD and other synucleinopathies, the unmet needs, and future perspectives.
引用
- Bellomo G, De Luca CMG, Paoletti FP, et al. α-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies: The Way Forward. Neurology. 2022. PMID: 35914941. doi:10.1212/WNL.0000000000200878
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。